Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06828796 · ClinicalTrials.gov registry record · Phase 2
Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide
A Phase 2 study of Hematopoietic Cell Transplant and Hematologic Disease and Disorders, sponsored by Northside Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06828796: Recruiting Phase 2 study of Hematopoietic Cell Transplant and Hematologic Disease and Disorders, sponsored by Northside Hospital.
NCT06828796 is a Phase 2 study of Hematopoietic Cell Transplant and Hematologic Disease and Disorders that is actively recruiting participants, run by Northside Hospital. The registered enrollment target is 20 participants, below the 386-participant average among 6 other Hematopoietic Cell Transplant trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06828796, a Phase 2 study of Hematopoietic Cell Transplant and Hematologic Disease and Disorders, is actively recruiting participants, sponsored by Northside Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
To evalute the safety and efficacy in reducing Cytokine Release Syndrome after hematopoietic stem cell transplantation by introducing immunosuppression earlier in the transplant process
Primary Outcome
Evaluate the incidence of CRS during the first 5 days following stem cell transplant by recording signs and symptoms based on CTCAE v5.0.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Tacrolimus
- DRUG Mycofenolate mofetil
Study Locations (1)
Georgia
- Northside Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-07-03 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 2 |
What NCT06828796 shows while recruiting
NCT06828796 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 386-participant average among 6 other Hematopoietic Cell Transplant trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Hematopoietic Cell Transplant appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT06828796 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT06828796 about?
NCT06828796 is a clinical study titled "Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide". To evalute the safety and efficacy in reducing Cytokine Release Syndrome after hematopoietic stem cell transplantation by introducing immunosuppression earlier in the transplant process
What is the current status of trial NCT06828796?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-07-03. Estimated completion is 2028-06-30.
What conditions does trial NCT06828796 study?
This clinical trial studies the following conditions: Hematopoietic Cell Transplant, Hematologic Disease and Disorders.
What interventions are being tested in trial NCT06828796?
The interventions under investigation include: Cyclophosphamide (DRUG), Tacrolimus (DRUG), Mycofenolate mofetil (DRUG).
Who is sponsoring clinical trial NCT06828796?
This trial is sponsored by Northside Hospital, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06828796 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic Cell Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients
RECRUITING
-
Cognitive Training Intervention and Attitudes Towards Genetics
RECRUITING · NA
-
The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients
RECRUITING · NA
-
Virtual Rehabilitation in HCT
RECRUITING · NA
-
Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients
ACTIVE NOT RECRUITING
-
Study of Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI